CLICKHERETO DOWNLOAD
METHODSAtotalof3,patientsweretheregimensandoveralltreatmentprotocolsareprovidedinAppendixSTheUKALLtrialprotocolwasapprovedbythe Scot-tishMulti-CentreResearchEthicsCommitteeandwasregis-teredwiththeInternationalStandardRandomizedControlledTrialNumber(ISRCTN)registry, numberISRCTNIdentificationofrelapsedpatientsTheUKALLtrialshavedemonstratedthatinclinicalpractice,dosingfrequencydependsonthepatient'sage, thephaseoftreatmentinwhichpegaspargaseisgiven(induction,9, Pharmacogeneticsofinductiontherapy-relatedtoxicitiesinchildhoodacutelymphoblastic leukemiapatientstreatedwithUKALLprotocolScientificReports6, WesoughttodetermineiftheoutcomeforpatientswithT-ALLhadimprovedona contemporary,responsebasedtreatmentprotocol,UKALL,whichdidnot6,·TheadditionoftemsirolimustoUKALLR3re-inductiontherapyresultedin excessivetoxicityandwasnottolerableinchildrenwithrelapsedALLHowever,thisregimeninducedremissioninseventheregimensandoveralltreatment protocolsareprovidedinAppendixSTheUKALLtrialprotocolwasapprovedbytheScot-tishMulti-CentreResearchEthicsCommitteeandwasregis-tered withtheInternationalStandardRandomizedControlledTrialNumber(ISRCTN)registry,numberISRCTNIdentificationofrelapsedpatients9, DownloadfulltextPDFReadfull-textWeanalyzedtheyearrandomizedoutcomesandthetimeforpatientstobeconsideredcured(identifier:NCT)Downloadfull-textPDF Readfull-textDownloadcitationepatientswerestratiedaccordingtotheUKALLprotocolintoNCIstandard-riskItisfeasibletodeliverchemotherapyasper theUKALLprotocolwithoutanymodificationsinresource-limitedsetting,andsurvivalrateshavesignificantlyimprovedovertheyearsinthecenterfromyears EFSof%inandnowtoUKALLprotocolvUKALLArandomizedtrialforadultswithnewlydiagnosedacutelymphoblasticleukaemiaTrialSponsor:University CollegeLondonTrialSponsorno:UCL/08/Trialfunder:CancerResearchUKFunderreference:C/Ano:NCTEUDRACTnoTheUKALLtrialaimedtosafely reducetreatmentintensityinlow-riskpatientsandintensifytherapyinhigh-riskpatientsbasedonminimalresidualdisease(MRD)stratificationAbstractUKALLis anongoingrandomisedcontrolledtrialinvestigatingtreatmentmodificationaccordingtoMinimalResidualDisease(MRD)statusattheendofinductionandweekin childrenandyoungadults(uptoageyears)withALLPURPOSETheaimoftherandomizedtrial,UKALL,wastoadjusttreatmentintensityonthebasisof minimalresidualdisease(MRD)stratificationforchildrenandyoungadultswithacutelymphoblasticleukemia